You are here: Home: Audio Program Guide: CCU Live Think Tank 2008: CCU Live Think Tank 2008 Audio
 
 

  Faculty Panel Discussion


  
Track 1 Use of chemotherapy-free intervals in the treatment of metastatic colorectal cancer (mCRC)
Track 2 Patient reactions to complete “treatment holidays”
Track 3 Case discussion: A man in his seventies with minimal mCRC who had a treatment holiday after developing severe skin toxicity from cetuximab
Track 4 Selection of patients with mCRC for chemotherapy-free intervals versus maintenance 5-FU/bevacizumab
Track 5 Natural history of Stage II versus Stage III CRC: Lessons from the ACCENT data set
Track 6 K-ras mutation status and response to anti-EGFR antibody therapies
Track 7 Considerations in the use of systemic therapy for patients with potentially resectable, curable hepatic metastases
Track 8 Impact of neoadjuvant oxaliplatin- versus irinotecan-containing regimens on hepatic function
Track 9 Preoperative versus postoperative systemic therapy for potentially resectable hepatic metastases
Track 10 Surgical and systemic treatment for synchronous primary and metastatic CRC
Track 11 Preliminary safety data of adjuvant bevacizumab in NSABP-C-08
Track 12 BRiTE observational study: Continuation of bevacizumab beyond disease progression and overall survival
audio
Track 13 SWOG-S0600 (iBET): Irinotecan-based chemotherapy and cetuximab with or without bevacizumab for patients with mCRC progressing on first-line therapy
audio
Track 14 Clinical use of bevacizumab beyond disease progression
audio
Track 15 Critical appraisal of the BRiTE study results
audio
Track 16 Management of mCRC progressing on first-line therapy
Track 17 Potential longer-term safety concerns with adjuvant bevacizumab
Track 18 Use of K-ras mutation status in clinical decision-making
Track 19 Converting unresectable hepatic metastases to resectable disease
Track 20 Referral to high-volume centers for resection of hepatic metastases
Track 21 Systemic adjuvant therapy for Stage II colon cancer
Track 22 Counseling patients with Stage II colon cancer about the potential risks and benefits of adjuvant therapy
Track 23 Communicating absolute and relative risk and benefit information to patients
Track 24 Use of adjuvant therapy after neoadjuvant chemoradiation therapy and surgery for rectal cancer
Track 25 Evaluation of bevacizumab in rectal cancer clinical trials
Track 26 Efficacy and safety of bevacizumab as a radiosensitizer
audio
Track 27 Clinical use of a neoadjuvant oxaliplatin-containing regimen with radiation therapy in rectal cancer
audio
Track 28 Combination therapy with cetuximab, bevacizumab and chemotherapy in mCRC
audio
Track 29 Defining clinical trial endpoints in studies of biologic therapy
audio